SAN DIEGO, CA--(Marketwire - October 16, 2008) - Lpath, Inc. (OTCBB: LPTN) announced that it has initiated dosing in its Phase 1 clinical trial with iSONEP™, the company's drug candidate for age-related macular degeneration (AMD) and possibly for other ocular diseases.
